施贵宝(BMY)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BMY 施贵宝

未开盘 04-24 16:00:00 EDT

48.86

-0.13

-0.27%

盘后49.15

+0.29+0.59%

19:59 EDT

最高49.05	最低48.55	成交量1,606万
今开49.00	昨收48.99	日振幅1.01%
总市值990.27亿	流通市值988.26亿	总股本20.27亿
成交额7.83亿	换手率0.79%	流通股本20.23亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"BMY","market":"US","secType":"STK","nameCN":"施贵宝","latestPrice":48.86,"timestamp":1713988800000,"preClose":48.99,"halted":0,"volume":16057141,"hourTrading":{"tag":"盘后","latestPrice":49.15,"preClose":48.86,"latestTime":"19:59 EDT","volume":306314,"amount":14967111.1897,"timestamp":1714003153051},"delay":0,"floatShares":2022631220,"shares":2026758715,"eps":3.86,"marketStatus":"未开盘","marketStatusCode":0,"change":-0.13,"latestTime":"04-24 16:00:00 EDT","open":49,"high":49.045,"low":48.55,"amount":783239880.26889,"amplitude":0.010104,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":3.86,"exchange":"NYSE","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1714032000000},"adr":0,"listingDate":-18475200000,"adjPreClose":48.99,"adrRate":0,"dividendRate":0.047278,"preHourTrading":{"tag":"盘前","latestPrice":49.1,"preClose":48.99,"latestTime":"09:29 EDT","volume":11805,"amount":579293.814915,"timestamp":1713965395799},"postHourTrading":{"tag":"盘后","latestPrice":49.15,"preClose":48.86,"latestTime":"19:59 EDT","volume":306314,"amount":14967111.1897,"timestamp":1714003153051},"volumeRatio":1.603553,"optionData":{"bulkOrders":[{"symbol":"BMY","call":true,"expireDate":1718942400000,"strike":"57.5","timestamp":1713966937632,"price":0.10999999940395355,"volume":1790,"amount":19690,"type":"+"},{"symbol":"BMY","call":false,"expireDate":1718942400000,"strike":"60.0","timestamp":1713985028672,"price":11.050000190734863,"volume":1740,"amount":1922700,"type":"-"}]}},"requestUrl":"/m/hq/s/BMY","defaultTab":"news","newsList":[{"id":"2430462500","title":"未来一天的看点 - 4月25日星期四","url":"https://stock-news.laohu8.com/highlight/detail?id=2430462500","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2430462500?lang=zh_cn&edition=full","pubTime":"2024-04-25 02:30","pubTimestamp":1713983434,"startTime":"0","endTime":"0","summary":"美国劳工部的每周失业救济申请数据可能会显示，在截至4月20日的一周内，各州首次申请失业救济的人数增加了3000人，经季节性因素调整后为215000人。与此同时，首次领取失业救济金的人数可能从截至4月13日当周的181.2万人降至180.5万人。美国航空公司将公布第一季度财报。由于主要市场需求低迷，陶氏预计将公布第一季度收入下降的报告。烟草巨头 Altria 将公布第一季度业绩。受客户转向广告流媒体的帮助，Roku 第一季度收入预计将增长 14.52%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2429619039","title":"百时美施贵宝  预计每股亏损4.42美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2429619039","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2429619039?lang=zh_cn&edition=full","pubTime":"2024-04-23 21:36","pubTimestamp":1713879371,"startTime":"0","endTime":"0","summary":"   * 百时美施贵宝公司将于4月25日公布截至2024年3月31日的财报，预计该公司的季度收入将有所增长。   * LSEG 分析师对百时美施贵宝公司的平均预期是每股亏损 4.42 美元。* 华尔街对百时美施贵宝公司 12 个月目标价的中位数为 55.00 美元，高于其上次收盘价 49.14 美元。4月23日 - 上一季度业绩。除非另有说明，所有数字均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2429070942","title":"更新版 1-百时美施贵宝与 Cellares 签订价值 3.8 亿美元的 CAR-T 疗法供应协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2429070942","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2429070942?lang=zh_cn&edition=full","pubTime":"2024-04-22 19:43","pubTimestamp":1713786237,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 )) (全文增加细节)    路透社4月22日 - 制药商百时美施贵宝  表示，已与合同制造商Cellares签署了一项价值3.8亿美元的协议，在美国、欧盟和日本生产其CAR-T细胞疗法。由于需求不断增长，这项合作将有助于百时美施贵宝扩大其生产能力。该公司今年 2 月表示，今年将在一些新的国家推出 CAR-T 血液癌症疗法 Abecma 和 Breyanzi。CAR-T疗法包括移除患者自身的T细胞--免疫系统的一个关键组成部分--对其进行工程改造，使其能够识别和攻击恶性细胞，然后重新注入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2429694178","title":"百时美施贵宝与 Cellares 达成 3.8 亿美元 CAR-T 疗法供应协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2429694178","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2429694178?lang=zh_cn&edition=full","pubTime":"2024-04-22 19:06","pubTimestamp":1713784005,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透社4月22日 - 百时美施贵宝  和Cellares公司周一表示，他们已达成一项3.8亿美元的协议，为更多患者提供CAR-T细胞疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2427575146","title":"百时美施贵宝下跌1.23%，报48.52美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2427575146","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2427575146?lang=zh_cn&edition=full","pubTime":"2024-04-13 03:05","pubTimestamp":1712948710,"startTime":"0","endTime":"0","summary":"4月13日，百时美施贵宝(BMY)盘中下跌1.23%，截至03:05，报48.52美元/股，成交3.47亿美元。财务数据显示，截至2023年12月31日，百时美施贵宝收入总额450.06亿美元，同比减少2.5%；归母净利润80.25亿美元，同比增长26.84%。大事提醒：4月25日，百时美施贵宝将于(美东)盘前披露2024财年一季报。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/13030540224641.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2425622667","title":"百时美施贵宝：精神分裂症疗法KarXT临床试验数据向好","url":"https://stock-news.laohu8.com/highlight/detail?id=2425622667","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2425622667?lang=zh_cn&edition=full","pubTime":"2024-04-07 14:15","pubTimestamp":1712470501,"startTime":"0","endTime":"0","summary":"百时美施贵宝：用于评估KarXT效果的emergent-4临床试验数据结果正面。数据表明，受试对象的精神分裂症状出现改善。按阳性与阴性症状量表的总体评估，经过一年的试验，超过75%的受试病患的症状较参照基准出现高出30%的改善。症状在开始试验的第二周，那些原来被安排在安慰剂对照组的被试的症状显著减轻，但在剩余的时间内保持稳定。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404071415518af9935c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404071415518af9935c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425681360","title":"布里斯托尔-迈尔斯公司的精神分裂症药物在后期研究中减轻症状而不增加体重","url":"https://stock-news.laohu8.com/highlight/detail?id=2425681360","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2425681360?lang=zh_cn&edition=full","pubTime":"2024-04-07 01:15","pubTimestamp":1712423708,"startTime":"0","endTime":"0","summary":" Sneha  S K    路透社4月6日 - 布里斯托尔-迈尔斯-施贵宝  公司周六表示，对其实验性精神分裂症药物进行的后期研究数据显示，该药物有助于减轻精神分裂症的症状，而不会出现其他抗精神病药物常见的体重增加的副作用。该公司表示，该药物的长期数据巩固了之前短期研究的结果。数据显示，KarXT 能在 52 周内平均减轻体重 2.56 公斤。该公司表示，最常见的不良反应是恶心和呕吐，其中大多数是轻微和短暂的。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2424825549","title":"百时美施贵宝下跌1.21%，报52.1美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2424825549","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2424825549?lang=zh_cn&edition=full","pubTime":"2024-04-03 23:38","pubTimestamp":1712158723,"startTime":"0","endTime":"0","summary":"4月3日，百时美施贵宝(BMY)盘中下跌1.21%，截至23:38，报52.1美元/股，成交1.4亿美元。财务数据显示，截至2023年12月31日，百时美施贵宝收入总额450.06亿美元，同比减少2.5%；归母净利润80.25亿美元，同比增长26.84%。大事提醒：4月25日，百时美施贵宝将于(美东)盘前披露2024财年一季报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/03233840121919.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2424710588","title":"百时美施贵宝下跌1.26%，报53.55美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2424710588","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2424710588?lang=zh_cn&edition=full","pubTime":"2024-04-01 21:46","pubTimestamp":1711979180,"startTime":"0","endTime":"0","summary":"4月1日，百时美施贵宝(BMY)盘中下跌1.26%，截至21:46，报53.55美元/股，成交4477.9万美元。财务数据显示，截至2023年12月31日，百时美施贵宝收入总额450.06亿美元，同比减少2.5%；归母净利润80.25亿美元，同比增长26.84%。大事提醒：4月25日，百时美施贵宝将于(美东)盘前披露2024财年一季报。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/01214640083531.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2424714336","title":"BUZZ-肺癌药物在晚期试验中达到主要目标后，Zai Lab业绩大增","url":"https://stock-news.laohu8.com/highlight/detail?id=2424714336","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2424714336?lang=zh_cn&edition=full","pubTime":"2024-04-01 21:00","pubTimestamp":1711976413,"startTime":"0","endTime":"0","summary":"    4月1日 - ** 在美国上市的中国制药商Zai Lab Ltd  盘前股价大涨3.3%至16.55美元。** ZLab的合作伙伴百时美施贵宝  周四晚些时候表示，其药物 KRAZATI在一项针对突变非小细胞肺癌 的晚期研究中达到了主要目标。** 该药物还达到了研究的一个关键次要目标 ** ZLAB预计将于今年 向中国医药产品协会提交KRAZATI的新药申请，作为该适应症 的二线或后线治疗药物。** BMY将完成对现有数据的全面评估 ，并与卫生部门讨论评估结果** 截至周四收盘，ZLAB 的美 股累计下跌 41.4","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2423210220","title":"百时美施贵宝(BMY.US)药物Zeposia治疗克罗恩病3期试验失败","url":"https://stock-news.laohu8.com/highlight/detail?id=2423210220","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2423210220?lang=zh_cn&edition=full","pubTime":"2024-03-29 11:06","pubTimestamp":1711681599,"startTime":"0","endTime":"0","summary":"智通财经获悉，百时美施贵宝(BMY.US)表示，其药物Zeposia治疗中重度活动性克罗恩病的3期研究在第12周未能达到主要临床缓解终点。该研究是YELLOWSTONE 3期临床试验两项为期12周的诱导研究中的第一项。该公司在声明中没有提及第二项研究的进展情况。Zeposia，也被称为ozanimod，已经被FDA批准用于治疗多发性硬化症和溃疡性结肠炎。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1096136.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2423235221","title":"百时美施贵宝的肠道疾病药物未能达到后期研究的主要目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2423235221","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2423235221?lang=zh_cn&edition=full","pubTime":"2024-03-29 04:05","pubTimestamp":1711656323,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透社3月28日 - 百时美施贵宝  周四表示，其治疗克罗恩病（一种慢性炎症性肠病）的实验性药物在一项后期研究中没有达到主要目标。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2422571739","title":"百时美施贵宝CEO博科思：继续优化创新药定价和支付体系","url":"https://stock-news.laohu8.com/highlight/detail?id=2422571739","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2422571739?lang=zh_cn&edition=full","pubTime":"2024-03-26 04:53","pubTimestamp":1711400001,"startTime":"0","endTime":"0","summary":"自国家医保药品目录开始规律性更新后，创新药在中国上市后纳入医保目录的速度越来越快。不过，随后的入院及临床推广环节，仍存在一些堵点。3月24日，在2024年中国发展高层论坛的大健康产业专题研讨会上，跨国药企百时美施贵宝首席执行官博科思建议，通过加强医生培训，让创新药能更早惠及患者。博科思在发言中表示，需要建立完善的支持发展创新的价值链，才能让中国患者更好地享受到中国创新药行业发展的成果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032605052587b48669&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032605052587b48669&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422554892","title":"百时美施贵宝首席执行官博科思：中国在构建多层次医疗保障体系方面取得长足进步 分享到：","url":"https://stock-news.laohu8.com/highlight/detail?id=2422554892","media":"中国新闻网","top":-1,"share":"https://www.laohu8.com/m/news/2422554892?lang=zh_cn&edition=full","pubTime":"2024-03-25 13:30","pubTimestamp":1711344620,"startTime":"0","endTime":"0","summary":"3月24日下午举行了“大健康产业专题研讨会”，百时美施贵宝首席执行官博科思在“小组讨论一”环节表示：继续在医疗保险谈判和将治疗纳入医院之间建立无缝连接。从2020年开始，中国在构建多层次医疗保障体系方面取得了长足进步，在城市中，很多患者购买了可负担的商业健康保险，使其有了更好医保覆盖。很多一流和首创的药物已经被纳入了中国医保，但与此同时，将其列入医院配方仍然面临着阻碍。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403251331168b5fae75&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403251331168b5fae75&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2421810308","title":"百时美施贵宝上涨1.24%，报52.23美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2421810308","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2421810308?lang=zh_cn&edition=full","pubTime":"2024-03-22 22:30","pubTimestamp":1711117804,"startTime":"0","endTime":"0","summary":"3月22日，百时美施贵宝(BMY)盘中上涨1.24%，截至22:30，报52.23美元/股，成交9009.62万美元。财务数据显示，截至2023年12月31日，百时美施贵宝收入总额450.06亿美元，同比减少2.5%；归母净利润80.25亿美元，同比增长26.84%。大事提醒：4月25日，百时美施贵宝将于(美东)盘前披露2024财年一季报。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/03/22223039964892.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2421075510","title":"隔夜美股全复盘(3.22)| 三大股指集体收涨，苹果大跌4%，遭反垄断诉讼；美光大涨14%，业绩和指引均超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2421075510","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2421075510?lang=zh_cn&edition=full","pubTime":"2024-03-22 08:11","pubTimestamp":1711066318,"startTime":"0","endTime":"0","summary":"三大股指集体收涨，苹果大跌4%，遭反垄断诉讼；美光大涨14%，业绩和指引均超预期","market":"us","thumbnail":"https://img7.gelonghui.com/column/2/140.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/140.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/710414","is_publish_highlight":false,"gpt_icon":0},{"id":"2421500686","title":"美股越来越贵，但这里还有六只便宜股","url":"https://stock-news.laohu8.com/highlight/detail?id=2421500686","media":"巴伦周刊","top":-1,"share":"https://www.laohu8.com/m/news/2421500686?lang=zh_cn&edition=full","pubTime":"2024-03-22 07:37","pubTimestamp":1711064255,"startTime":"0","endTime":"0","summary":"最近大多数美股变得越来越贵，买便宜股是一个不错的策略，但要找对正确的操作方法。$美敦力$的股票相对便宜，而且波动不大。首先，这六只股票的市盈率都低于平均水平。问题在于，这六只股票之所以便宜是有原因的，所以它们中的任何一个都可能出现业绩不及预期的情况。如果等权重买入这六只股票，意味着未来一年投资者将获得4.5%的股息率。","market":"hk","thumbnail":"https://static.tigerbbs.com/69dee97b481043498231d48dcdf00dfa","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/69dee97b481043498231d48dcdf00dfa"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzU3MDc5NTU0NQ==&mid=2247554444&idx=2&sn=0e9172f5fb2ccdb1cb69ab2667912645&chksm=fdf78fc75e78a2e5b1d09a85681d48bacc976011a8fb22c69efcda18282c20f19a311aadd75a&scene=0#rd","is_publish_highlight":true,"gpt_icon":1},{"id":"2421723031","title":"施贵宝(BMY.US)Abecma获欧盟批准用于治疗复发/难治性多发性骨髓瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=2421723031","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2421723031?lang=zh_cn&edition=full","pubTime":"2024-03-21 10:38","pubTimestamp":1710988686,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，施贵宝(BMY.US)表示，其CAR T细胞疗法Abecma治疗复发或难治性多发性骨髓瘤已获得欧盟监管部门的批准。该疗法被批准用于之前至少接受过两种治疗的成年患者，包括免疫调节剂、蛋白酶体抑制剂和抗CD38抗体。施贵宝表示，该产品在欧盟也被认定为治疗多发性骨髓瘤的孤儿药。Abecma目前在美国已被批准用于治疗多发性骨髓瘤，并与2seventy bio(TSVT.US)联合商业化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1089581.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2420712069","title":"百时美施贵宝肝癌治疗达到后期研究的主要目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2420712069","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2420712069?lang=zh_cn&edition=full","pubTime":"2024-03-20 19:06","pubTimestamp":1710932776,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透社3月20日 - 百时美施贵宝  周三表示，其药物Opdivo和Yervoy的组合达到了一项晚期研究的主要目标，该研究将其作为一种肝癌的一线治疗方法进行评估。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bms.com","stockEarnings":[{"period":"1week","weight":0.0213},{"period":"1month","weight":-0.0649},{"period":"3month","weight":-0.0151},{"period":"6month","weight":-0.0423},{"period":"1year","weight":-0.3044},{"period":"ytd","weight":-0.0477}],"compareEarnings":[{"period":"1week","weight":0.0097},{"period":"1month","weight":-0.0276},{"period":"3month","weight":0.0356},{"period":"6month","weight":0.2307},{"period":"1year","weight":0.2446},{"period":"ytd","weight":0.0633}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"百时美施贵宝公司于1933年8月根据特拉华州法律注册成立，名为百时美公司，继承了1887年在纽约成立的一家企业。1989年，由于合并，公司更名为百时美施贵宝公司。公司在全球范围内从事生物制药产品的发现、开发、许可、制造、营销、分销和销售。他们在全球范围内从事生物制药产品的发现、开发、许可、制造、营销、分销和销售。 他们预计他们对Celgene和MyoKardia的收购将进一步将他们定位为领先的生物制药公司，通过多项近期资产和额外的外部合作伙伴扩大他们的肿瘤学、血液学、免疫学和心血管产品组合。","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":-0.013265},{"month":2,"riseRate":0.545455,"avgChangeRate":0.009113},{"month":3,"riseRate":0.636364,"avgChangeRate":0.008429},{"month":4,"riseRate":0.488889,"avgChangeRate":-0.000097},{"month":5,"riseRate":0.590909,"avgChangeRate":0.00511},{"month":6,"riseRate":0.613636,"avgChangeRate":0.010539},{"month":7,"riseRate":0.409091,"avgChangeRate":-0.003649},{"month":8,"riseRate":0.5,"avgChangeRate":-0.004242},{"month":9,"riseRate":0.522727,"avgChangeRate":0.010569},{"month":10,"riseRate":0.568182,"avgChangeRate":0.024004},{"month":11,"riseRate":0.613636,"avgChangeRate":0.020382},{"month":12,"riseRate":0.636364,"avgChangeRate":0.022108}],"exchange":"NYSE","name":"施贵宝","nameEN":"Bristol-Myers Squibb"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"施贵宝(BMY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供施贵宝(BMY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"施贵宝,BMY,施贵宝股票,施贵宝股票老虎,施贵宝股票老虎国际,施贵宝行情,施贵宝股票行情,施贵宝股价,施贵宝股市,施贵宝股票价格,施贵宝股票交易,施贵宝股票购买,施贵宝股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"施贵宝(BMY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供施贵宝(BMY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}